Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer



Status:Completed
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:55 - 85
Updated:5/3/2018
Start Date:January 2003
End Date:February 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men

Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as
leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal
suppression and demonstrate increased bone turnover and consequent bone loss at the hip and
spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.

A 6-month randomized, double-blind, placebo-controlled trial was conducted, including 40 men
aged ≥ 55 years receiving LHRH-agonist treatment for 6 months for locally advanced prostate
cancer. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip was
measured every 6 months. In addition, bone turnover markers including N-telopeptide, serum
C-telopeptide and procollagen peptide, and 25-OH vitamin D and intact parathyroid hormone
were measured at baseline and at 6 months.

Inclusion Criteria:

- Non-metastatic prostate cancer

- Men to receive Gonadotropin-releasing Hormone-agonist therapy

Exclusion Criteria:

- Other cancers except skin cancer

- Evidence of metabolic bone disease

- Prior use of bisphosphonates
We found this trial at
1
site
University of Connecticut Health Center
263 Farmington Ave
Farmington, Connecticut 06030
(860) 679-2000
University of Connecticut Health Center UConn Health is a vibrant, integrated academic medical center that...
?
mi
from
Farmington, CT
Click here to add this to my saved trials